Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE-J long-term safety of orforglipron in type 2 diabetes
jRCT2031230337Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of orforglipron in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Treatment-emergent adverse events. Started Sep 2023; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031230337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230337.